GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.



 
29.07.13 GlycoVaxyn AG has secured a Strategic Translation Award from the Wellcome Trust
26.06.13 GlycoVaxyn AG to Present at the IBC Bioconjugates Conference in San Diego, USA
13.06.13 GlycoVaxyn AG to Host 3rd Science Day in Beaune, France
 

GlycoVaxyn will be present during:

- 9th ISPPD Symposium in Hyderabad on March 9-13, 2014

- Annual Conference of the Society for Glycobiology in St. Petersburg (Florida) on November 17-20, 2013

- CEO New York Conference in New York on November 12-13, 2013